Equities

Indoco Remedies Ltd

INDOCO:NSI

Indoco Remedies Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)377.10
  • Today's Change4.15 / 1.11%
  • Shares traded61.91k
  • 1 Year change+10.62%
  • Beta0.6257
Data delayed at least 15 minutes, as of Sep 20 2024 11:26 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in INRIncome statement in INRView more

Year on year Indoco Remedies Ltd had net income fall -30.78% from 1.42bn to 984.60m despite a 8.91% increase in revenues from 16.69bn to 18.17bn. An increase in the selling, general and administrative costs as a percentage of sales from 40.20% to 43.37% was a component in the falling net income despite rising revenues.
Gross margin68.61%
Net profit margin4.10%
Operating margin7.84%
Return on assets--
Return on equity--
Return on investment--
More ▼

Cash flow in INRView more

In 2024, Indoco Remedies Ltd increased its cash reserves by 35.98%, or 39.31m. Cash Flow from Financing totalled 2.80bn or 15.43% of revenues. In addition the company generated 1.57bn in cash from operations while cash used for investing totalled 4.34bn.
Cash flow per share17.04
Price/Cash flow per share19.56
Book value per share--
Tangible book value per share--
More ▼

Balance sheet in INRView more

Indoco Remedies Ltd uses little or no debt in its capital structure.
Current ratio--
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼

Growth rates in INR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth dropped -33.33% and -30.79%, respectively. Additionally, five year annualized dividend per share growth ranks above the industry average relative to its peers.
Div yield(5 year avg)0.44%
Div growth rate (5 year)37.97%
Payout ratio (TTM)18.03%
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-40.48
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.